These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36579812)

  • 1. Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis.
    Hobbs J; Lowe J; Ferdinand A; Shook A; Beck B; Blais D; Borchardt C; Xu B
    J Oncol Pharm Pract; 2023 Dec; 29(8):1853-1861. PubMed ID: 36579812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy.
    McBride A; Alrawashdh N; Bartels T; Moore L; Persky D; Abraham I
    Future Oncol; 2021 Sep; 17(26):3485-3497. PubMed ID: 34241542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
    Kosaka Y; Rai Y; Masuda N; Takano T; Saeki T; Nakamura S; Shimazaki R; Ito Y; Tokuda Y; Tamura K
    Support Care Cancer; 2015 Apr; 23(4):1137-43. PubMed ID: 25576433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer.
    Wang X; He Y; Wang T; Xie Y; Li J; Ouyang T; Fan Z
    Support Care Cancer; 2019 Aug; 27(8):3019-3025. PubMed ID: 30607682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy.
    Mizuno Y; Fuchikami H; Takeda N; Iwai M; Sato K
    Jpn J Clin Oncol; 2017 Jan; 47(1):12-17. PubMed ID: 28122890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
    Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
    BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
    De Oliveira Brandao C; Lewis S; Sandschafer D; Crawford J
    Curr Med Res Opin; 2023 May; 39(5):707-718. PubMed ID: 36976784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
    Kourlaba G; Dimopoulos MA; Pectasides D; Skarlos DV; Gogas H; Pentheroudakis G; Koutras A; Fountzilas G; Maniadakis N
    Support Care Cancer; 2015 Jul; 23(7):2045-51. PubMed ID: 25524005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer.
    Alrawashdh N; Vraney J; Choi BM; Almutairi AR; Abraham I; McBride A
    Future Oncol; 2022 Jun; 18(19):2381-2390. PubMed ID: 35477322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
    Sohn BS; Jeong JH; Ahn JH; Jung KH; Kim JE; Sohn JH; Koh SJ; Seo JH; Lee KS; Kim SB
    Invest New Drugs; 2020 Jun; 38(3):866-873. PubMed ID: 31728715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients.
    Mori H; Kubo M; Kai M; Kurata K; Yamada M; Nakamura M
    Anticancer Res; 2018 Jul; 38(7):4381-4386. PubMed ID: 29970577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims.
    Weycker D; Hanau A; Lonshteyn A; Bowers C; Bensink M; Garawin T; Chandler D
    Curr Med Res Opin; 2018 Sep; 34(9):1705-1711. PubMed ID: 29962268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
    Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
    Waller CF; Ranganna GM; Pennella EJ; Blakeley C; Bronchud MH; Mattano LA; Berzoy O; Voitko N; Shparyk Y; Lytvyn I; Rusyn A; Popov V; Láng I; Beckmann K; Sharma R; Baczkowski M; Kothekar M; Barve A
    Ann Hematol; 2019 May; 98(5):1217-1224. PubMed ID: 30824956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
    Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
    Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
    Eckstrom J; Bartels T; Abraham I; Patel H; Elquza E; Scott AJ; Malangone S; Hollings J; McBride A
    Support Care Cancer; 2019 Mar; 27(3):873-878. PubMed ID: 30090991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
    von Minckwitz G; Kümmel S; du Bois A; Eiermann W; Eidtmann H; Gerber B; Hilfrich J; Huober J; Costa SD; Jackisch C; Grasshoff ST; Vescia S; Skacel T; Loibl S; Mehta KM; Kaufmann M;
    Ann Oncol; 2008 Feb; 19(2):292-8. PubMed ID: 17846019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.